Remove Communication Remove Pharmaceutical Companies Remove Pharmaceutical Manufacturing
article thumbnail

How ready are you? Preparing for the impact of EU GMP Annex 1 on primary packaging

European Pharmaceutical Review

Indeed, a key aspect of EU GMP Annex 1 is the requirement for pharmaceutical manufacturers to develop a comprehensive Contamination Control Strategy (CCS) that documents their approach to assuring the sterile drug product’s high quality and, therefore, enhancing patient safety.

article thumbnail

The Veterans’ Perspectives: Exploring the Shift in Healthcare

PharmaState Academy

” The first panel at the Now & Next Summit featured prominent figures from top pharmaceutical companies. The panel also highlights adaptive challenges in leadership, such as addressing generational changes, language and communication barriers, and the evolving needs of people within the healthcare and pharmaceutical industry.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New IFPMA and EFPIA guidance on use of social media by the pharmaceutical industry

pharmaphorum

The overarching principle set out in Codes of Practice, and in particular the Principles for the use of digital channels in the EFPIA Code , is that the legislation and Codes of Practice apply equally to communications by companies on social media and digital channels. What are the key points from the Guidance?

article thumbnail

Pharma gives UCPMP the thumbs up, health activists cry foul

Express Pharma

He mentions that OPPI member companies follow the stringent OPPI Code of Pharmaceutical Practices 2019 (OPPI Code) which is based on the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Code.

article thumbnail

Pharmaceutical Procurement Strategies Overview

Viseven

Unexpected geographic factors Many pharmaceutical companies relying on global markets for drug materials are particularly vulnerable to shifting geopolitical situations. For instance, depending on sources in tariff-affected countries can substantially increase a pharma company’s operational expenses.

article thumbnail

Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovation

pharmaphorum

As these innovations – which have the potential to be transformative for patients – enter uncharted regulatory territory, the pathway is not always clear or well-defined, which is why Astellas adopts a proactive approach to early communication with health authorities. “We About Astellas. Astellas Pharma Inc.

article thumbnail

Concept of validation in pharmaceutical industry

GMPSOP

By implementing robust validation protocols, pharmaceutical companies can ensure that their products are safe, effective, pure and of the highest quality. A scenario where validation is required The management of your company has recently decided to install an information management system in analytical laboratory. .